Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion

Gabriel Coscas*, Albert Augustin, Francesco Bandello, Marc D. De Smet, Paolo Lanzetta, Giovanni Staurenghi, Maria Cristina Parravano, Patricia Udaondo, Elad Moisseiev, Gisele Soubrane, Yossi Yatziv, Anat Loewenstein

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To review the current practice of retreatment with Ozurdex injections in patients with macu-lar edema (ME) secondary to retinal vein occlusion (RVO), and to recommend simple guidelines for Ozurdex reinjection in management of RVO. Methods: This was a multicenter retrospective study of patients who received more than 2 Ozurdex injections for the treatment of ME in RVO. Recorded parameters included percent of patients with a 15-letter gain, visual acuity (VA) improvement from baseline, change in central macular thickness (CMT), time to reinjection, and occurrence of any complications. Results: A total of 128 patients were included, 58 (45.3%) with central RVO (CRVO) and 70 (54.7%) with branch RVO (BRVO). Mean interval for Ozurdex reinjection was 5.9 months following the first injection and 8.7 months following the second. A >15-letter gain in VA was observed in 34 (48.8%) patients with CRVO and 16 (28%) patients with BRVO. Mean overall VA improvement at month 6 did not show significance (p>0.05); however, a significantly better mean VA improvement was seen in treatment-naïve eyes (p<0.03). The CMT was significantly reduced compared to baseline. The mean CMT decreased by 214.6 μm in eyes with BRVO (n = 53) and by 355.1 μm in eyes with CRVO (n = 63) (p = 0.002). Complication rates were very low. Conclusions: Repeated injections of Ozurdex are effective and have a favorable safety profile. In current practice, the retreatment interval with Ozurdex injections might be too long, precluding the full therapeutic potential of this treatment modality. A strategy for managing RVO patients treated with Ozurdex on an as-needed basis is provided.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalEuropean Journal of Ophthalmology
Volume24
Issue number1
DOIs
StatePublished - 14 Oct 2013

Keywords

  • Dexamethasone implant
  • Macular edema
  • Ozurdex
  • Retinal vein occlusion
  • Retreatment

Fingerprint

Dive into the research topics of 'Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion'. Together they form a unique fingerprint.

Cite this